GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Asset Turnover

GenMark Diagnostics (GenMark Diagnostics) Asset Turnover : 0.23 (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. GenMark Diagnostics's Revenue for the three months ended in Dec. 2020 was $50.1 Mil. GenMark Diagnostics's Total Assets for the quarter that ended in Dec. 2020 was $219.1 Mil. Therefore, GenMark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2020 was 0.23.

Asset Turnover is linked to ROE % through Du Pont Formula. GenMark Diagnostics's annualized ROE % for the quarter that ended in Dec. 2020 was -15.83%. It is also linked to ROA % through Du Pont Formula. GenMark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2020 was -6.80%.


GenMark Diagnostics Asset Turnover Historical Data

The historical data trend for GenMark Diagnostics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Asset Turnover Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.52 0.66 0.86 1.02

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.35 0.26 0.21 0.23

Competitive Comparison of GenMark Diagnostics's Asset Turnover

For the Medical Devices subindustry, GenMark Diagnostics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Asset Turnover falls into.



GenMark Diagnostics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

GenMark Diagnostics's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=171.554/( (111.473+223.534)/ 2 )
=171.554/167.5035
=1.02

GenMark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=50.08/( (214.59+223.534)/ 2 )
=50.08/219.062
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


GenMark Diagnostics  (NAS:GNMK) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

GenMark Diagnostics's annulized ROE % for the quarter that ended in Dec. 2020 is

ROE %**(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-14.896/94.0775
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.896 / 200.32)*(200.32 / 219.062)*(219.062/ 94.0775)
=Net Margin %*Asset Turnover*Equity Multiplier
=-7.44 %*0.9144*2.3285
=ROA %*Equity Multiplier
=-6.80 %*2.3285
=-15.83 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

GenMark Diagnostics's annulized ROA % for the quarter that ended in Dec. 2020 is

ROA %(Q: Dec. 2020 )
=Net Income/Total Assets
=-14.896/219.062
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-14.896 / 200.32)*(200.32 / 219.062)
=Net Margin %*Asset Turnover
=-7.44 %*0.9144
=-6.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


GenMark Diagnostics Asset Turnover Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008